Mitochondrial PAK6 inhibits prostate cancer cell apoptosis via the PAK6-SIRT4-ANT2 complex.

Abstract

Rationale: P21-activated kinase 6 (PAK6) is a member of the class II PAKs family, which is a conserved family of serine/threonine kinases. Although the effects of PAK6 on many malignancies, especially in prostate cancer, have been studied for a long time, the role of PAK6 in mitochondria remains unknown. Methods: The expression of PAK6, SIRT4 and ANT2 in prostate cancer and adjacent non-tumor tissues was detected by immunohistochemistry. Immunofuorescence and immunoelectron microscopy were used to determine the subcellular localization of PAK6. Immunoprecipitation, immunofuorescence and ubiquitination assays were performed to determine how PAK6 regulates SIRT4, how SIRT4 regulates ANT2, and how PAK6 regulates ANT2. Flow cytometry detection and xenograft models were used to evaluate the impact of ANT2 mutant expression on the prostate cancer cell cycle and apoptosis regulation. Results: The present study revealed that the PAK6-SIRT4-ANT2 complex is involved in mitochondrial apoptosis in prostate cancer cells. It was found that PAK6 is mainly located in the mitochondrial inner membrane, in which PAK6 promotes SIRT4 ubiquitin-mediated proteolysis. Furthermore, SIRT4 deprives the ANT2 acetylation at K105 to promote its ubiquitination degradation. Hence, PAK6 adjusts the acetylation level of ANT2 through the PAK6-SIRT4-ANT2 pathway, in order to regulate the stability of ANT2. Meanwhile, PAK6 directly phosphorylates ANT2 atT107 to inhibit the apoptosis of prostate cancer cells. Therefore, the phosphorylation and deacetylation modifications of ANT2 are mutually regulated, leading to tumor growth in vivo. Consistently, these clinical prostate cancer tissue evaluations reveal that PAK6 is positively correlated with ANT2 expression, but negatively correlated with SIRT4. Conclusion: These present findings suggest the pivotal role of the PAK6-SIRT4-ANT2 complex in the apoptosis of prostate cancer. This complex could be a potential biomarker for the treatment and prognosis of prostate cancer.

• Authors: Tingting Li, Yang Li, Tong Liu, Bingtao Hu, Jiabin Li, Chen Liu, Tao Liu, Feng Li
• Journal: Theranostics (Theranostics) Vol. 10 Issue 6 Pg. 2571-2586 ( 2020) ISSN: 1838-7640 [Electronic] Australia
• PMID: 32194820 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The author(s).

Chemical References

• Adenine Nucleotide Translocator 2
• Biomarkers, Tumor
• Mitochondrial Proteins
• PAK6 protein, human
• p21-Activated Kinases
• SIRT4 protein, human
• Sirtuins

Topics

• Adenine Nucleotide Translocator 2 (metabolism)
• Adenocarcinoma (metabolism)
• Animals
• Apoptosis
• Biomarkers, Tumor (metabolism)
• HEK293 Cells
• Humans
• Male
• Mice
• Mice, Inbred NOD
• Mice, Nude
• Mice, SCID
• Mitochondria (metabolism)
• Mitochondrial Proteins (metabolism)
• PC-3 Cells
• Prostatic Neoplasms (metabolism)
• Sirtuins (metabolism)
• p21-Activated Kinases (metabolism)